Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

@article{SnchezRovira2000PhaseIT,
  title={Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.},
  author={Pedro S{\'a}nchez-Rovira and Ana Ja{\'e}n and Enrique Jos{\'e} San Emeterio Gonz{\'a}lez and Ignacio Porras and Michael R Due{\~n}as and Bego{\~n}a Medina and Nicol{\'a}s Mohedano and Margarita Fernandez and M. Jos{\'e} Martos and Ana Bel{\'e}n Lozano},
  journal={Clinical breast cancer},
  year={2000},
  volume={1 3},
  pages={226-32}
}
The present trial was designed to determine the efficacy of the combination of gemcitabine/doxorubicin/paclitaxel (GAT) delivered every other week as first-line therapy in patients with metastatic breast cancer. From February 1998 to September 1999, 41 patients were included in this trial. Doses delivered were doxorubicin 30 mg/m2 on day 1 and paclitaxel 135 mg/m2 plus gemcitabine 2500 mg/m2 both given on day 2, every 14 days. Doses were selected from a previous phase I trial conducted at our… CONTINUE READING